加拿大与CSL Seqirus签订新的大流行病防备合同，提供佐剂细胞疫苗。
This contract solidifies CSL Seqirus's role in national biosecurity for Canada, ensuring access to advanced influenza vaccines during a pandemic. It demonstrates the company's capability to secure large-scale government contracts and highlights the strategic importance of its cell-based vaccine technology for public health preparedness.
This agreement directly enhances Canada's national biosecurity and public health infrastructure by securing a supply of advanced influenza vaccines for pandemic response, reinforcing CSL Seqirus's position in the Canadian market.
Enhances Canada's pandemic response capabilities.
CSL Seqirus strengthens its government partnership portfolio.
Canada secures new pandemic preparedness contract with CSL Seqirus.
Contract covers adjuvanted cell-based influenza vaccines.
Enhances Canada's pandemic response capabilities.
加拿大已与流感疫苗领域的全球领导者 CSL Seqirus 达成一项新的大流行病防范合同。根据协议，一旦世界卫生组织 (WHO) 宣布发生流感大流行，CSL Seqirus 将提供佐剂细胞培养流感疫苗以支持加拿大。该合同加强了加拿大的生物安全和应对能力。
登录后可保存信号笔记。
登录